Abstract Lynch syndrome is one of the most common hereditary colorectal cancer (CRC) syndrome and is caused by germline mutations of MLH1, MSH2 and more rarely MSH6, PMS2, MLH3 genes. Whereas the absence of MSH2 protein is predictive of Lynch syndrome, it is not the case for the absence of MLH1 protein. The purpose of this study was to develop a sensitive and cost effective algorithm to select Lynch syndrome cases among patients with MLH1 immunohistochemical silencing. Eleven sporadic CRC and 16 Lynch syndrome cases with MLH1 protein abnormalities were selected. The BRAF c.1799T[ A mutation (p.Val600Glu) was analyzed by direct sequencing after PCR amplification of exon 15. Methylation of MLH1 promoter was determined by Methylation-Sensitive SingleStrand Conformation Analysis. In patients with Lynch syndrome, there was no BRAF mutation and only one case showed MLH1 methylation (6%). In sporadic CRC, all cases were MLH1 methylated (100%) and 8 out of 11 cases carried the above BRAF mutation (73%) whereas only 3 cases were BRAF wild type (27%). We propose the following algorithm: (1) no further molecular analysis should be performed for CRC exhibiting MLH1 methylation and BRAF mutation, and these cases should be considered as sporadic CRC; (2) CRC with unmethylated MLH1 and negative for BRAF mutation should be considered as Lynch syndrome; and (3) only a small fraction of CRC with MLH1 promoter methylation but negative for BRAF mutation should be true Lynch syndrome patients. These potentially Lynch syndrome patients should be offered genetic counselling before searching for MLH1 gene mutations.
Introduction
Lynch syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) syndrome is one of the most common hereditary colon cancer syndrome, accounting for 3-6% of the total colorectal cancer burden [1] , and is caused by germline mutations of mismatch repair (MMR) genes [2, 3] . MLH1 and MSH2 are the most commonly mutated MMR genes in HNPCC, with mutations in MSH6 and PMS2 being significantly less common and MLH3 mutations very rare [3, 4] . Complete inactivation in any of the MMR genes result in genomic instability, most evident within repetitive mononucleotide or dinucleotide microsatellite DNA sequences which are particularly prone to replication errors [5] . The resulting microsatellite instability (MSI) is widely used as a prescreen in patients candidates for HNPCC according to standardised methodology, and tumours with a significant instability are referred to as MSI-high (MSI-H) [6] . Nevertheless, approximately 10-15% of all sporadic CRCs are also MSI-H, although these show no association with HNPCC [7] . These common MSI-H sporadic tumours do not result from a predisposing constitutive MMR gene mutation, and typically show loss of expression of MLH1 protein consecutive to mono-or bi-allelic hypermethylation of the gene promoter [8] .
Sporadic MSI-H colorectal cancers and Lynch syndrome superficially resemble each other in that they are frequently located in the proximal colon and share morphological features such as mucin production and tumour-infiltrating lymphocytes [9] . However, they have been shown to differ in terms of demographics, molecular alterations and natural history [10] [11] [12] . These two subsets of MSI-H colorectal cancer need to be distinguished and investigated separately since the identification of Lynch syndrome warrants specific management policies with respect to genetic screening and surveillance measures in both the patients and their first-degree relatives.
The most effective strategy for the diagnosis of Lynch syndrome is the compilation of a thorough family history of colorectal cancer and fulfilment of the Amsterdam criteria [13, 14] . However, this information is often not available and about 20% of Lynch syndrome families with germline mutations do not meet these criteria [15] . Current laboratory testing algorithms for patients with suspected Lynch syndrome typically include a prescreen step, in which MSI testing and/or MMR protein immunohistochemistry (IHC) are performed on tumour tissue prior to more laborious and costly efforts aimed at identifying mutations in the responsible MMR genes. Patients whose tumours show loss of MSH2 expression almost invariably have an underlying MSH2 or MSH6 germline mutation [16, 17] . As mentioned above MSI-H CRC cancers with loss of MLH1 protein expression are more difficult to classify into familial versus sporadic CRC categories because the underlying germline MLH1 mutation or methylation of the MLH1 gene promoter cannot be distinguished a priori. Therefore, analysis of MLH1 promoter methylation status can be a valuable mean to spare unnecessary genetic testing in patients with sporadic MSI-H tumours [18, 19] . However, as our results strongly suggest, this strategy is not sufficient because MLH1 promoter methylation is not exclusive to sporadic CRC [20] [21] [22] [23] [24] .
Recently, activating mutations in the BRAF protooncogene have been associated with MSI-H tumours in general [25] , and subsequently with the sporadic subset in particular, providing a further avenue for distinction between familial and sporadic MSI-H tumours [26] [27] [28] [29] .
Here, we present the results of a comparative study where we determined the methylation status of MLH1, and the presence of BRAF mutations in both sporadic MSI-H cancers with loss of expression of MLH1 protein, and MLH1 mutated HNPCC patients. The aim of the study was (1) to determine whether MLH1 methylation and BRAF mutations might be used as negative predictors for HNPCC in patients with MSI-H tumours, and (2) to design a cost effective algorithm for the detection of MLH1 mutated HNPCC patients.
Methods

Patients
Sixteen patients with Lynch syndrome harbouring an MLH1 constitutive mutation were selected from an anonymised series investigated at the Institut Central des Hôpitaux Valaisans in Sion, Switzerland. In addition, eleven patients with sporadic MSI-H CRC and lacking of MLH1 protein expression were selected from a previously studied series after clinical genetic screening [19] .
Immunohistochemistry
Immunohistochemical expression of MLH1 was investigated as follows for each slide, dewaxed paraffin sections were immunostained using the streptavidin-biotin peroxidase complex method. Four micrometre thick tissue sections were mounted on aminopropylmethoxysilane-coated glass slides, deparaffinized in xylol, taken through to absolute alcohol, and blocked for endogenous peroxidase with 1% hydrogen peroxide in methanol for 45 min. Slides were then heated in a microwave oven for 15 min in 10 mM citrate buffer pH 6.0. To reduce nonspecific binding, they were incubated in normal goat serum (Pel-Freez Biologicals, Rogers, Arkansas) diluted 1:30 in TBS for 10 min. Sections were then incubated for 30 min with the primary monoclonal antibodies for the gene products of MLH1 (1:100, Pharmingen, Basel). Following the primary antibody incubation, the sections were incubated for 30 min with goat anti-mouse IgG (Sternberger, Baltimore, MD, USA) diluted 1:100 in NFDM/TBS, and with PAPcomplex diluted 1:600 in NFDM/TBS. Peroxidase activity was revealed with 3,3 0 -diaminobenzidine as the chromogen, and the sections were counterstained with Mayer's acid-free hematoxylin. As a negative control, the monoclonal primary antibody was replaced by hybridoma supernatant of a similar isotype but without reactivity in the tissue examined.
MSI analysis
For MSI analysis, microdissection was performed after selection of tumour tissue by a pathologist (H.B.). DNA was extracted from tumour cells and from normal mucosa from two different blocks to avoid contamination. Purified DNA was amplified by PCR, using the reference panel of microsatellite primers recommended for colorectal cancer by the National Cancer Institute which includes the markers BAT25, BAT26, D5S346 (APC), D2S123 (-MSH2), and D17S250 (p53). The presence of additional bands in the PCR products from tumour DNA that were not observed in DNA from corresponding normal tissue was scored as unstable at that particular locus. Tumour samples were classified as reflecting high-frequency microsatellite instability (MSI-H) when instability was observed for 2 or more of the loci screened, low-frequency microsatellite instability when less than 2 of the loci screened were unstable, or microsatellite stability, when stability was present at all the loci tested.
MLH1 methylation analysis
Methylation was by Methylation-Sensitive Single-Strand Conformation Analysis [30] . After deparaffinization and staining in 0.1% toluidine blue, histologically selected areas in tissue sections were manually microdissected. Only the tumour cells were retained and final histological control before collection of the tumour cells confirmed that contamination with other cells was negligible. Extracted DNA was modified with sodium bisulfite. A 178-bp fragment of the MLH1 gene promoter was amplified by nested PCR using the following primers: FW 5 0 -GATTTTTTAAG GTTAAGAG-3 0 and RV 5 0 -ATAAAACCCTATACCTA ATC-3 0 for the outer PCR and FW 5 0 -TTTTTAGGAGTGA AGGAG-3 0 and RV 5 0 -AAACCCTATACCTAATCTAT C-3 0 for the inner PCR amplification. The outer PCR amplification was performed with 2 ll of modified DNA in a total volume of 20 ll for 40 cycles. Twenty cycles were performed for the inner PCR. Amplification products were confirmed by visualization on a 2% agarose gel. Singlestrand conformation analysis was performed as previously described [30] . The percentage of methylated alleles was semiquantitatively estimated by comparing the intensity of the methylated and unmethylated bands.
Detection of BRAF V600E mutation Genomic DNA was extracted from fixed materials using the DNeasy Tissue Kit (Qiagen, Hilden, Germany). DNA was eluted with 60 lL of elution buffer and kept at -20°C. The most common T1799A transversion mutation (BRAF V600E) was studied by direct sequencing after PCR amplification of exon 15 of the BRAF gene. DNA was amplified using the following primers: forward 5 0 -TCTTC ATAATGCTTGCTCTGATAG-3 0 ; reverse 5 0 -TGGAAAA ATAGCCTCAATTCTTAC-3 0 . Sequencing with the internal primer 5 0 -TCTACTGTTTTCCTTTACTTACT-3 0 was performed colorimetrically using the BigDye Terminator v3.1 Cycle Sequencing Kit on an ABI PRISM 3770 genetic analyzer (AppliedBiosystems, Foster City, CA, USA).
Germline mutation analysis
Complete screening for both point mutations and gross deletions in the MLH1gene (NM 251.2) was performed on genomic DNA from each proband. Exons and adjacent splice junctions were amplified by PCR and both DNA strands were sequenced. To standardize bidirectional sequencing, M13-21 and M13REV primers were added as tails at either primer of the pair corresponding to a specific exon. Genomic rearrangements, mostly as large deletions, were searched for using multiplex ligation-dependent probe amplification (MLPA, MRC-Holland). Mutation nomenclature follows HGVS guidelines (www.hgvs.org) with number one corresponding to ''A'' of the initiating translation codon. The presence of a pathogenic germline mutation in the proband was confirmed from a second sample of peripheral blood.
Results
The results are summarised in Table 1 . All cases (100%) of sporadic MSI-H MLH1 silenced CRC were MLH1 methylated. Eight out of 11 cases carried the BRAF mutation (73%) whereas 3 cases were BRAF wild type (27%). In MLH1 mutated HNPCC patients, one case showed MLH1 methylation (6%) and none of the cases was BRAF mutated (0%). Sporadic MLH1 silenced CRC and MLH1 mutated HNPCC were subdivided into 4 groups according to their MLH1 et BRAF status: Group 1 of sporadic CRC: 8/11 (73%) presented with BRAF mutation and MLH1 methylation; Group 2 of sporadic CRC: 3/11 (27%) presented with BRAF wild type and MLH1 methylation; Group 3 of HNPCC: 15/16 (94%) harboured a BRAF wild type and were MLH1 unmethylated; Goup 4 of HNPCC: 1/16 (6%) were BRAF wild type and MLH1 methylated.
When we added all sporadic MLH1 silenced CRC and MLH1 mutated Lynch syndrome we found that 4 cases (15%) out of 27 MSI-H CRC presented with both BRAF wild type and MLH1 methylation gene.
Algorithm for Lynch syndrome detection 169
Discussion
Germline mutations in mismatch repair (MMR) genes affecting mainly MSH2 and MLH1 cause susceptibility to Lynch syndrome or HNPCC, a dominant inherited disorder accounting for approximately 2-5% of all cases of CRC [2, [31] [32] [33] . The identification of patients with a pathogenic MMR mutation is a major issue because morbidity and mortality from CRC can be reduced by early and intensive screening [1, 18, [34] [35] [36] . However, the diagnosis of Lynch syndrome is hampered by the lack of simple and specific diagnostic criteria. Because MSI resulting from defective MMR is a hallmark of tumours arising in the Lynch syndrome [1, 3] , international criteria have been developed to combine clinical and molecular features to help identify patients at high risk of a diagnosis of Lynch syndrome [15] . Current recommendations include a prescreen phase by analysis of tumours for the presence of MSI and the absence of at least one MMR protein expression by immunohistochemistry (IHC) [6, 37, 38] . Results from IHC allow to target the relevant gene which needs to be extensively analyzed. In this context, available data show that an abnormal immunostaining of MSH2 and MSH6 proteins is most likely the result of germline mutations [16, 17] . MSI-H CRC with loss of MLH1 protein are more difficult to interpret and classify as MLH1 extinction is also observed in approximately 10-15% of sporadic CRC, as a result of epigenetic silencing of the MLH1 gene by methylation of the promoter region [8] . The aim of this study was to evaluate strategy that would select more effectively MLH1 mutated HNPCC patients. This is of major importance as the search for a causative germline mutation remains the most time-consuming and expensive step of the entire approach. In a previously published study of a series of MSI-H CRC patients, we proposed a cost effective and time saving procedure for MLH1 mutated Lynch syndrome cases detection algorithm [19] . Selection of MSI and IHC analysis represented the first step in Lynch syndrome detection and in cases of abnormal expression of MLH1 protein, the search for a MLH1 methylation represented the second step. In the present study, we wished to improve the selection of MLH1 mutated HNPCC patients by adding the search for BRAF mutation, and this was evaluated in a series of sporadic CRC negative for an MLH1 mutation and familial HNPCC positive for an MLH1 mutation. In this report, we examined the prevalence of MLH1 methylation in MLH1 mutated HNPCC and sought to determine whether the presence of a MLH1 methylator phenotype is informative to improve selection of true HNPCC patients. Overall, there was significantly less MLH1 gene-promoter methylation in HNPCC patients when compared with sporadic cancers that were MSI-H. Only 6% of HNPCC cases were methylated in the MLH1 promoter region, compared to all MLH1 negative sporadic MSI-H cases. At 100%, the level of MLH1 methylation in sporadic tumours was consistent with previous findings [8, 21, 22, 39] . It has been suggested that HNPCC cancers, although characterised by an MSI-H phenotype, show significantly less methylation than their sporadic counterparts, and by inference, are driven by an alternative mechanism acting as the 'second hit' required to inactivate the wild-type allele in HNPCC such as allelic loss [29, 40] . The important variability of methylation levels reported to be associated with MLH1 in Lynch syndrome is likely to reflect selection of different CpG-rich regions of the promoter examined between studies [24, 41] .
Recently, an oncogenic V600E (previously known as V599E) hotspot mutation in BRAF, a kinase encoding gene from the RAS/RAF/MAPK pathway, has been found in colorectal tumours that show MMR deficiency [25, 42, 43] . Moreover, it has been shown that these mutations occur almost exclusively in tumours located in the proximal colon and with hypermethylation of MLH1, the gene involved in the initial steps of development of these tumours [26, 28] . However, in more detailed analyses, BRAF mutations were not detected in those cases with or presumed to have a germline mutation in either MLH1 or MSH2 [28, 44] . In a recent study, Loughrey et al. [45] , demonstrated the clinical validity and utility of V600E mutation testing in a familial cancer clinic setting. Since mutation in BRAF is present in the majority of tumours with hypermethylation of the MLH1 promoter but not in cases with germline MLH1 mutations, the combination of microsatellite instability testing, MLH1 hypermethylation, and BRAF (V600E) mutation analysis best distinguishes sporadic CRC from Lynch syndrome. In our series reported in the present report, we have shown that BRAF-V600E mutation was absent in 100% of MLH1 mutated HNPCC, and was detected in 73% of MSI-H MLH1 negative sporadic colorectal tumours, thus absent in 27% of this group. In addition, our data indicated a significant correlation between a BRAF mutation and MLH1 methylation in sporadic MSI-H MLH1 negative CRC and a significant correlation of a BRAF wild type and MLH1 unmethylation in Lynch syndrome patients, as observed by others [29, 43, 46] . Overall, tumours that have the BRAF V600E mutation and exhibit MLH1 promoter hypermethylation are almost certainly sporadic, whereas tumours that show neither are most likely inherited. Although the above strategy allows to classify 85% of MSI-H CRC into HNPCC and sporadic variants, HNPCC cases with MLH1 methylation and sporadic CRC cases without mutation of BRAF gene remain more difficult to classify. Nevertheless, this group represented only 15% of all MSI-H CRCs studied. This strategy has helped tightening the analysis on a small group of cancers with unclear genetic profile and for which a genetic counselling and sequencing MLH1 mutation should be offered.
On the basis of our results we recommend the incorporation of BRAF V600E mutation and MLH1 methylation testing into the laboratory algorithm for pre-screening patients with suspected HNPCC, whose CRCs show loss of expression of MLH1 protein. In summary, our data suggest the following algorithm ( Fig. 1): (1) no further molecular analysis should be performed in cases of colorectal tumours with MLH1 methylation and BRAF mutation and these cases should be considered as sporadic CRC; (2) colorectal tumours with unmethylated MLH1 and negative for BRAF mutation should be considered as Lynch syndrome; (3) among CRC with MLH1 promoter methylation but negative for BRAF mutation, only a subset of patients are expected to be true Lynch syndrome. Genetic counselling should be offered before searching for MLH1 gene mutations. The proposed algorithm allows to spare time-consuming and costly efforts associated with unnecessary whole gene analysis. 
